The Peptide Field
Menu

4 FDA label and trial tables · Checked

Joint pain vs placebo, out of 100 people

Forteo label

Placebo8.4%
On Forteo10.1%

In the Forteo label, 10.1% on Forteo had joint pain (arthralgia). On placebo, 8.4% did.

See all 4 tables

Every table that lists joint pain

Each dot is 1 in 100 people.

Reported it Rest of a dose range Did not report it

Filled dots show the low end of a range. Dots are rounded. The exact number is above each grid.

FDA-approved medicines

EgriftaFDA-approved product

Adults with HIV and extra belly fat

Row in the source: Joint pain (arthralgia)

Placebo11%
On Egrifta13%
Who was studied
Adults with HIV and lipodystrophy in placebo-controlled trials. 543 got Egrifta and 263 got placebo.
How long
26 weeks
Source
Egrifta WR prescribing information on DailyMed . FDA label revised March 2025.

ForteoFDA-approved product

Women and men with osteoporosis

Row in the source: Joint pain (arthralgia)

Placebo8.4%
On Forteo10.1%
Who was studied
1,382 adults aged 28 to 86. 691 got Forteo and 691 got placebo. Everyone also took calcium and vitamin D. The middle trial length was 11 months for men and 19 months for women.
How long
11 months (men), 19 months (women)
Source
Forteo prescribing information on DailyMed . FDA label revised August 2026.

TymlosFDA-approved product

Men with osteoporosis

Row in the source: Joint pain (arthralgia)

Placebo1%
On Tymlos7%
Who was studied
Men aged 42 to 85. 149 men got Tymlos and 79 got placebo.
How long
12 months
Source
Tymlos prescribing information on DailyMed . FDA label revised August 2026.

Medicines that are not FDA-approved

CagrilintideNo FDA-approved product

Phase 2 weight trial (NCT03856047), less common problems

Row in the source: Joint pain (arthralgia)

Placebo6.9%
On cagrilintide (by dose)1.0% to 5.9%
Who was studied
706 adults without diabetes who had obesity, or overweight with high blood pressure or unhealthy blood-fat levels. 506 got cagrilintide and 101 got placebo. A liraglutide group of 99 is not shown.
How long
26 weeks of treatment, side effects counted to week 32
Source
ClinicalTrials.gov posted results . Trial registry results posted July 18, 2023.

How long were people watched?

Each bar is one set of trials. The dots on this page come only from the time inside each bar.

Stated length Range in the source

  1. Egrifta, adults with HIV26 weeks

  2. Forteo, adults with osteoporosis11 months (men), 19 months (women)

  3. Tymlos, men12 months

  4. Cagrilintide, phase 226 weeks of treatment, side effects counted to week 32

Trials can miss rare harms and harms that take years to appear.

Other side effects

Pick a medicine and side effect

Where the numbers come from

Every number is copied from a table on our side effect pages. Those tables come from FDA labels on DailyMed, results posted on ClinicalTrials.gov, and company trial results. We did not add, total, or rank any number. Rows keep one fixed order: FDA-approved medicines first, then the rest, each in A to Z order.

We group rows by name. For example, “Tiredness (fatigue)” and “Tiredness or weakness (fatigue)” are both under tiredness. Each row still shows its own words from the source.

The tables on this site copy part of each label, such as the most common problems. A problem missing from one table may still have happened.

Report a side effect

You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.

Did this page answer your question?